Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

L. Mega, Jessica; Simon, Tabassome; Collet, Jean‐Philippe; L. Anderson, Jeffrey; M. Antman, Elliott; P. Bliden, Kevin; P. Cannon, Christopher; Danchin, Nicolas; Giusti, Betti; A. Gurbel, Paul; D. Horne, Benjamin; Hulot, Jean-Sebastian; Kastrati, Adnan; Montalescot, Gilles; Neumann, Franz‐Josef; Shen, Lei; Sibbing, Dirk; Gabríel Steg, Philippe; Trenk, Dietmar; D. Wiviott, Stephen; S. Sabatine, Marc

doi:10.1001/jama.2010.1543

Public

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

Published in JAMA • Oct 26, 2010

Authors:

Jessica L. Mega

Tabassome Simon

Jean‐Philippe Collet

Abstract

CONTENT: Clopidogrel, one of the most commonly prescribed medications, is a prodrug requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes. OBJECTIVE: To define th...

Subject

Medicine

Clopidogrel

Percutaneous coronary intervention

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!